全文获取类型
收费全文 | 2466379篇 |
免费 | 178724篇 |
国内免费 | 4368篇 |
专业分类
耳鼻咽喉 | 33037篇 |
儿科学 | 79723篇 |
妇产科学 | 65153篇 |
基础医学 | 361094篇 |
口腔科学 | 65089篇 |
临床医学 | 220113篇 |
内科学 | 483249篇 |
皮肤病学 | 53046篇 |
神经病学 | 196976篇 |
特种医学 | 93219篇 |
外国民族医学 | 491篇 |
外科学 | 373965篇 |
综合类 | 50149篇 |
现状与发展 | 13篇 |
一般理论 | 853篇 |
预防医学 | 191046篇 |
眼科学 | 55729篇 |
药学 | 182470篇 |
17篇 | |
中国医学 | 5537篇 |
肿瘤学 | 138502篇 |
出版年
2021年 | 21001篇 |
2019年 | 21001篇 |
2018年 | 36937篇 |
2017年 | 28363篇 |
2016年 | 32338篇 |
2015年 | 27761篇 |
2014年 | 38646篇 |
2013年 | 57093篇 |
2012年 | 81212篇 |
2011年 | 90973篇 |
2010年 | 55398篇 |
2009年 | 51189篇 |
2008年 | 85744篇 |
2007年 | 92282篇 |
2006年 | 83580篇 |
2005年 | 82311篇 |
2004年 | 79087篇 |
2003年 | 77019篇 |
2002年 | 73585篇 |
2001年 | 109725篇 |
2000年 | 112552篇 |
1999年 | 94358篇 |
1998年 | 27619篇 |
1997年 | 24285篇 |
1996年 | 24525篇 |
1995年 | 23184篇 |
1994年 | 21331篇 |
1993年 | 19964篇 |
1992年 | 72340篇 |
1991年 | 70509篇 |
1990年 | 68808篇 |
1989年 | 66005篇 |
1988年 | 60588篇 |
1987年 | 59398篇 |
1986年 | 55514篇 |
1985年 | 53256篇 |
1984年 | 39479篇 |
1983年 | 33505篇 |
1982年 | 19941篇 |
1979年 | 36011篇 |
1978年 | 25712篇 |
1977年 | 21215篇 |
1976年 | 20374篇 |
1975年 | 21821篇 |
1974年 | 26205篇 |
1973年 | 24847篇 |
1972年 | 23262篇 |
1971年 | 22078篇 |
1970年 | 20304篇 |
1969年 | 19375篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy 相似文献
13.
14.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
15.
16.
17.
Abd-Allah H. El Ashmawy Kathleen Dowson Ahmed El-Bakoury Hazem A.H. Hosny Rathan Yarlagadda Jonathan Keenan 《The Journal of arthroplasty》2021,36(3):816-822.e1
BackgroundTotal hip and knee arthroplasties are increasingly performed operations, and routine follow-up places huge demands on orthopedic services. This study investigates the effectiveness, patients’ satisfaction, and cost reduction of Virtual Joint Replacement Clinic (VJRC) follow-up of total hip arthroplasty and total knee arthroplasty patients in a university hospital. VJRC is especially valuable when in-person appointments are not advised or feasible such as during the COVID-19 pandemic.MethodsA total of 1749 patients who were invited for VJRC follow-up for knee or hip arthroplasty from January 2017 to December 2018 were included in this retrospective study. Patients were referred to VJRC after their 6-week postoperative review. Routine VJRC postoperative review was undertaken at 1 and 7 years and then 3-yearly thereafter. We evaluated the VJRC patient response rate, acceptability, and outcome. Patient satisfaction was measured in a subgroup of patients using a satisfaction survey. VJRC costs were calculated compared to face-to-face follow-up.ResultsThe VJRC had a 92.05% overall response rate. Only 7.22% required further in-person appointments with only 3% being reviewed by an orthopedic consultant. VJRC resulted in an estimated saving of £42,644 per year at our institution. The patients’ satisfaction survey showed that 89.29% of the patients were either satisfied or very satisfied with VJRC follow-up.ConclusionVJRC follow-up for hip and knee arthroplasty patients is an effective alternative to in-person clinic assessment which is accepted by patients, has high patient satisfaction, and can reduce the cost to both health services and patients. 相似文献
18.
19.
目的 基于网络药理学和分子对接技术探究黄芪-赤芍配伍对治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的作用机制。方法 利用TCMSP,Pharmmaper数据库,筛选黄芪-赤芍治疗COPD的活性成分和潜在靶点;结合Genecards数据库挖掘的COPD相关靶点,对黄芪-赤芍药对与COPD靶点进行PPI网络构建,交互处理得到黄芪-赤芍药对治疗COPD的关键靶点,并进行GO分析和KEGG通路富集分析;并采用分子对接技术将主要活性成分与TNF-α(肿瘤坏死因子),IL-6(白细胞介素6)等进行分子对接;最后利用A549炎症细胞与人脐静脉内皮细胞缺氧损伤模型进行体外细胞实验对结果加以验证。结果 黄芪-赤芍药对中44个有效成分作用于COPD,核心成分为:槲皮素、山奈酚、丁子香萜、芍药苷、(2R,3R)-4-methoxyl-distylin、二氢异黄酮;黄芪-赤芍药对通过IL6、PTGS2、TNF等113个靶蛋白,调控Ras、PI3KAkt、IL-17等多条信号通路治疗COPD,且分子对接结果显示槲皮素、山奈酚、丁子香萜、芍药苷与IL-6、PTGS2、TNF大分子蛋白有良好的结合性,体外细胞试验证实,槲皮素与山奈酚均能减少IL-8,MMP-9炎症因子的分泌,具有不同程度的抗炎效果;芍药苷有明显的扩血管、抗血栓之效。结论 黄芪-赤芍药对治疗COPD具有多成分、多靶点、多通路、整体调节的作用特点。初步揭示了黄芪-赤芍药对通过抑制炎症反应、调节上皮细胞生长增强保护屏障等预测出黄芪-赤芍药对治疗COPD的潜在作用机制,以期为其活性成分的药效物质基础提供理论研究和思路。 相似文献
20.